Coordinating Investigator of the Phase 2 pediatric study, former Chairman of the College of Pediatrics at the Universite Claude Bernard Lyon 1, and Professor Emeritus of Pediatrics, stated, "I am highly encouraged by the mean annualized height velocity achieved by once-weekly TransCon Growth Hormone
in the Phase 2 pediatric study.
Parathyroid hormone values were similar in patients who received growth hormone
compared with those who did not, despite marked differences in final rates of bone formation.
The authors hope that with additional work, these results will guide more informed use of growth hormone
or growth hormone
analogs for promoting muscle development and reducing muscle loss.
This formula proves to be an analog of growth hormone
releasing hormone, or GHRH.
Early treatment with growth hormone
improves growth retardation and bone mineral density without short-term desirable effects," observed the lead author Fernando Santos, MD, PhD, of the Hospital Universitario Central de Asturias, Oviedo, Spain.
We believe that these positive Phase II data indicate that our proprietary protein crystallization technology can effectively deliver long-acting growth hormone
therapy to growth hormone
deficient patients through a once-weekly injection using a fine-gauge needle," said Dr.
In the clinical trials, volunteers who took growth hormone
experienced significantly more swelling in joints and extremities, more carpal tunnel syndrome, and more joint pain than did participants who received a placebo.
first synthesized in 1985 under the Reagan Orphan drug act, to treat dwarfism, was quickly recognized to stop aging in its tracks and reverse it to a remarkable degree.
7 billion market for growth hormone
Research leading to the development of the company's long acting growth hormone
analogs has been supported by two Small Business Innovation Research grants awarded to Bolder BioTechnology by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.
Patients were randomized to receive 4 mg of recombinant human growth hormone
daily, delivered subcutaneously; 4 mg of growth hormone
on alternate days; or placebo.
The research suggests patients treated with growth hormone
before the mid-1980s have an increased risk of dying from bowel cancer or Hodgkin's disease.